Search

Displaying results 2881 - 2890 of 4234 in total
  1. Drug

    Cloxacillin

    go.drugbank.com/drugs/DB01147
    ApprovedInvestigationalVet approved

    A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.

  2. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Unlike the monoclonal antibody PCSK9 inhibitors ([evolocumab], [alirocumab]), enlicitide is administered orally as a once-daily tablet. … It is formulated as enlicitide decanoate alongside the permeation enhancer sodium caprate, which facilitates absorption of the peptide across the gastrointestinal tract, though oral bioavailability remains

  3. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

  4. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...

  5. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

  6. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  7. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.

  8. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...

  9. Drug

    Demeclocycline

    go.drugbank.com/drugs/DB00618
    Approved

    A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

  10. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid sig...